Open Label, Single Center Study to Evaluate Higher Doses of Daptomycin in the Treatment of Patients With Severe Necrotizing Skin and Soft Tissue Infections.

Trial Profile

Open Label, Single Center Study to Evaluate Higher Doses of Daptomycin in the Treatment of Patients With Severe Necrotizing Skin and Soft Tissue Infections.

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Nov 2015

At a glance

  • Drugs Daptomycin (Primary)
  • Indications Gram-positive infections; Skin and soft tissue infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 May 2008 The expected completion date for this trial is now 1 May 2008, according to ClinicalTrials.gov.
    • 30 May 2008 Status changed from recruiting to completed, reported by ClinicalTrials.gov.
    • 09 Jul 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top